The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 24, 2026
Filed:
May. 11, 2022
Applicant:
Genzyme Corporation, Cambridge, MA (US);
Inventors:
Zhongli Gao, Bridgewater, NJ (US);
Gregory Hurlbut, Bridgewater, NJ (US);
Mark Munson, Bridgewater, NJ (US);
Junkai Liao, Bridgewater, NJ (US);
Assignee:
Genzyme Corporation, Cambridge, MA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 239/69 (2006.01); A61K 31/4418 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4965 (2006.01); A61K 31/497 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61P 11/00 (2006.01); C07D 213/76 (2006.01); C07D 241/22 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01);
U.S. Cl.
CPC ...
C07D 239/69 (2013.01); A61K 31/4418 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/4965 (2013.01); A61K 31/497 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); A61P 11/00 (2018.01); C07D 213/76 (2013.01); C07D 241/22 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07B 2200/07 (2013.01);
Abstract
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.